AbbVie Says Botox Exempt From Medicare Price Negotiations

Дата публикации: 25-09-2026 19:30:05

AbbVie largely backed away from its constitutional challenges to the Inflation Reduction Act's Drug Price Negotiation Program in D.C. federal court Friday, but still insisted that its suite of Botox drugs can't be forced into negotiations with Medicare over price because they feature enough human plasma to fit into a congressional exemption.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FCC Insists DC District Lacks Jurisdiction In Fight With ABC	0	6.72	25-09-2026
2	Vein Tech Maker Escapes Suit Over DOJ Kickback Probe	0	9.63	23-09-2026
3	Novartis Beats Patent Listing Suit Over Entresto	0	7.9	24-09-2026
4	TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation	0	8.67	27-04-2026
5	DC Circ. Judges Clash Over Fate Of Deported Venezuelans	0	5.78	25-09-2026
6	CPSC Told To Explain Warning Against Weighted Baby Blankets	0	6.15	25-09-2026
7	Blue Shield Still Facing Therapy 'Ghost Network' Suit	0	7.36	23-09-2026
8	United States: Court Reinforces Duty to Respond to Congressional Subpoenas	0	8.1	21-08-2026
9	Суд присяжных США обязал Apple выплатить рекордные $5,7 млрд	0	17.69	27-09-2026
10	Lipoprotein(a)-Lowering Medication Agent to Reduce Cardiovascular Events	0	12.34	25-09-2026

Классификация: Международные. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.94. Источник: www.law360.com.